 Tamara Perry
Concepts (232)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 30 | 2025 | 282 | 8.530 |
Why?
| | Hypersensitivity | 10 | 2023 | 76 | 3.270 |
Why?
| | Allergens | 17 | 2021 | 137 | 3.030 |
Why?
| | Food Hypersensitivity | 11 | 2023 | 98 | 2.840 |
Why?
| | Telemedicine | 8 | 2023 | 465 | 2.500 |
Why?
| | Schools | 5 | 2023 | 162 | 1.560 |
Why?
| | Rural Population | 8 | 2022 | 549 | 1.440 |
Why?
| | Child | 41 | 2024 | 6849 | 1.320 |
Why?
| | Environmental Exposure | 8 | 2023 | 201 | 1.240 |
Why?
| | School Health Services | 4 | 2023 | 48 | 1.150 |
Why?
| | Anti-Asthmatic Agents | 4 | 2025 | 29 | 1.110 |
Why?
| | Dermatitis, Atopic | 3 | 2023 | 39 | 0.990 |
Why?
| | Healthcare Disparities | 5 | 2022 | 282 | 0.970 |
Why?
| | Peanut Hypersensitivity | 8 | 2019 | 85 | 0.890 |
Why?
| | Spirometry | 3 | 2022 | 30 | 0.850 |
Why?
| | Metformin | 1 | 2023 | 63 | 0.830 |
Why?
| | Humans | 64 | 2025 | 49929 | 0.830 |
Why?
| | Air Pollution | 1 | 2023 | 44 | 0.810 |
Why?
| | Air Pollutants | 1 | 2023 | 64 | 0.800 |
Why?
| | Health Status Disparities | 3 | 2021 | 196 | 0.800 |
Why?
| | Delivery of Health Care | 3 | 2022 | 308 | 0.800 |
Why?
| | Adolescent | 23 | 2024 | 6417 | 0.790 |
Why?
| | Air Pollution, Indoor | 4 | 2014 | 25 | 0.750 |
Why?
| | Health Services Accessibility | 3 | 2021 | 417 | 0.740 |
Why?
| | Immunoglobulin E | 8 | 2019 | 91 | 0.730 |
Why?
| | Desensitization, Immunologic | 7 | 2020 | 105 | 0.670 |
Why?
| | Skin Tests | 9 | 2019 | 55 | 0.660 |
Why?
| | Physicians | 1 | 2022 | 229 | 0.620 |
Why?
| | Arkansas | 13 | 2024 | 1990 | 0.590 |
Why?
| | Health Communication | 1 | 2017 | 22 | 0.550 |
Why?
| | Poverty | 2 | 2023 | 207 | 0.540 |
Why?
| | Urban Population | 4 | 2018 | 151 | 0.510 |
Why?
| | Reminder Systems | 1 | 2015 | 27 | 0.500 |
Why?
| | Child, Preschool | 21 | 2024 | 3879 | 0.490 |
Why?
| | Housing | 2 | 2006 | 46 | 0.480 |
Why?
| | Patient Education as Topic | 1 | 2018 | 315 | 0.480 |
Why?
| | Cockroaches | 1 | 2014 | 3 | 0.460 |
Why?
| | Self Care | 1 | 2015 | 135 | 0.460 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2014 | 16 | 0.460 |
Why?
| | Male | 31 | 2024 | 25454 | 0.440 |
Why?
| | Adrenal Cortex Hormones | 2 | 2025 | 99 | 0.440 |
Why?
| | Female | 31 | 2024 | 26576 | 0.430 |
Why?
| | Caregivers | 4 | 2019 | 212 | 0.390 |
Why?
| | Rural Health | 2 | 2009 | 88 | 0.380 |
Why?
| | Medicaid | 2 | 2024 | 255 | 0.380 |
Why?
| | United States | 10 | 2024 | 4883 | 0.380 |
Why?
| | Food Supply | 2 | 2023 | 91 | 0.360 |
Why?
| | Anaphylaxis | 3 | 2016 | 71 | 0.350 |
Why?
| | Socioeconomic Factors | 3 | 2023 | 584 | 0.320 |
Why?
| | Cats | 2 | 2006 | 79 | 0.310 |
Why?
| | Epinephrine | 4 | 2016 | 97 | 0.300 |
Why?
| | Egg Hypersensitivity | 3 | 2020 | 26 | 0.300 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2025 | 550 | 0.280 |
Why?
| | Immunization | 3 | 2017 | 63 | 0.280 |
Why?
| | Suburban Population | 1 | 2006 | 7 | 0.280 |
Why?
| | Dust | 3 | 2014 | 22 | 0.260 |
Why?
| | Patient Selection | 2 | 2018 | 254 | 0.250 |
Why?
| | Self Efficacy | 2 | 2017 | 130 | 0.240 |
Why?
| | Risk Factors | 8 | 2024 | 3605 | 0.240 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2004 | 8 | 0.240 |
Why?
| | Respiratory System | 1 | 2004 | 27 | 0.240 |
Why?
| | Quinolines | 1 | 2004 | 41 | 0.240 |
Why?
| | Acetates | 1 | 2004 | 49 | 0.230 |
Why?
| | Patient Satisfaction | 2 | 2017 | 278 | 0.230 |
Why?
| | Minority Groups | 2 | 2022 | 131 | 0.230 |
Why?
| | Diagnostic Errors | 1 | 2004 | 65 | 0.230 |
Why?
| | Avoidance Learning | 1 | 2003 | 16 | 0.230 |
Why?
| | Prevalence | 5 | 2019 | 956 | 0.220 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 380 | 0.220 |
Why?
| | Risk Reduction Behavior | 1 | 2003 | 58 | 0.220 |
Why?
| | Poverty Areas | 1 | 2003 | 37 | 0.220 |
Why?
| | Vitamin D Deficiency | 1 | 2023 | 44 | 0.220 |
Why?
| | Emergency Service, Hospital | 5 | 2024 | 487 | 0.210 |
Why?
| | Administration, Oral | 8 | 2020 | 433 | 0.210 |
Why?
| | Educational Status | 1 | 2023 | 224 | 0.200 |
Why?
| | Morbidity | 3 | 2023 | 128 | 0.200 |
Why?
| | Infant | 11 | 2024 | 3575 | 0.200 |
Why?
| | Virus Diseases | 1 | 2022 | 40 | 0.200 |
Why?
| | Trust | 1 | 2022 | 61 | 0.190 |
Why?
| | Lung Diseases | 1 | 2022 | 96 | 0.190 |
Why?
| | Parents | 1 | 2003 | 320 | 0.180 |
Why?
| | Disease Progression | 1 | 2023 | 820 | 0.180 |
Why?
| | Allergy and Immunology | 2 | 2024 | 19 | 0.170 |
Why?
| | Absenteeism | 1 | 2019 | 17 | 0.170 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 1576 | 0.160 |
Why?
| | Sympathomimetics | 2 | 2016 | 21 | 0.160 |
Why?
| | Adult | 6 | 2025 | 13356 | 0.160 |
Why?
| | Antigens, Plant | 3 | 2013 | 14 | 0.160 |
Why?
| | Patient Dropouts | 1 | 2018 | 51 | 0.150 |
Why?
| | Glycoproteins | 3 | 2013 | 115 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 76 | 0.150 |
Why?
| | Basophils | 2 | 2015 | 15 | 0.150 |
Why?
| | Community Health Services | 1 | 2018 | 101 | 0.140 |
Why?
| | Eosinophils | 1 | 2017 | 43 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2017 | 39 | 0.140 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 149 | 0.140 |
Why?
| | Health Literacy | 1 | 2019 | 130 | 0.140 |
Why?
| | Animals | 5 | 2014 | 13100 | 0.140 |
Why?
| | Esophagus | 1 | 2017 | 84 | 0.140 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 43 | 0.140 |
Why?
| | Models, Statistical | 1 | 2018 | 225 | 0.140 |
Why?
| | Quality Improvement | 1 | 2018 | 205 | 0.130 |
Why?
| | Young Adult | 2 | 2023 | 4031 | 0.130 |
Why?
| | Basophil Degranulation Test | 1 | 2015 | 3 | 0.130 |
Why?
| | Hospitalization | 3 | 2024 | 663 | 0.120 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2015 | 20 | 0.120 |
Why?
| | Advisory Committees | 1 | 2014 | 61 | 0.120 |
Why?
| | Plant Proteins | 3 | 2015 | 67 | 0.110 |
Why?
| | Meningitis, Pneumococcal | 1 | 2013 | 7 | 0.110 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 11 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2024 | 6124 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2018 | 953 | 0.110 |
Why?
| | Forced Expiratory Volume | 2 | 2022 | 44 | 0.110 |
Why?
| | Lactose Intolerance | 1 | 2013 | 1 | 0.110 |
Why?
| | Mycobacterium fortuitum | 1 | 2013 | 6 | 0.110 |
Why?
| | Macrolides | 1 | 2013 | 16 | 0.110 |
Why?
| | Manikins | 1 | 2013 | 35 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.110 |
Why?
| | Emergency Medicine | 1 | 2013 | 52 | 0.110 |
Why?
| | Clarithromycin | 1 | 2013 | 38 | 0.110 |
Why?
| | Clindamycin | 1 | 2012 | 13 | 0.100 |
Why?
| | Methicillin | 1 | 2012 | 11 | 0.100 |
Why?
| | House Calls | 1 | 2012 | 26 | 0.100 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 72 | 0.100 |
Why?
| | Odds Ratio | 2 | 2019 | 548 | 0.100 |
Why?
| | Prospective Studies | 4 | 2023 | 2345 | 0.090 |
Why?
| | Influenza Vaccines | 1 | 2011 | 31 | 0.090 |
Why?
| | Quality of Life | 3 | 2025 | 838 | 0.090 |
Why?
| | Influenza, Human | 1 | 2011 | 83 | 0.090 |
Why?
| | Pediatrics | 1 | 2013 | 280 | 0.090 |
Why?
| | Risk | 2 | 2016 | 314 | 0.090 |
Why?
| | Bronchitis | 1 | 2010 | 11 | 0.090 |
Why?
| | Demography | 1 | 2010 | 93 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1037 | 0.080 |
Why?
| | Mice | 2 | 2014 | 5658 | 0.080 |
Why?
| | Immune Tolerance | 2 | 2011 | 84 | 0.080 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 269 | 0.080 |
Why?
| | Immunotherapy | 1 | 2011 | 235 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2012 | 327 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2013 | 679 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2177 | 0.080 |
Why?
| | Recurrence | 1 | 2010 | 658 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 193 | 0.070 |
Why?
| | New York | 2 | 2018 | 49 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2013 | 347 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 116 | 0.070 |
Why?
| | Antigens, Dermatophagoides | 1 | 2006 | 3 | 0.070 |
Why?
| | Animals, Domestic | 1 | 2006 | 8 | 0.070 |
Why?
| | Maryland | 1 | 2006 | 32 | 0.070 |
Why?
| | Dogs | 1 | 2006 | 185 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 742 | 0.070 |
Why?
| | Adrenergic beta-Agonists | 1 | 2025 | 41 | 0.060 |
Why?
| | Sulfides | 1 | 2004 | 28 | 0.060 |
Why?
| | Cyclopropanes | 1 | 2004 | 23 | 0.060 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2004 | 6 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2019 | 184 | 0.060 |
Why?
| | Administration, Inhalation | 1 | 2025 | 111 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2004 | 60 | 0.060 |
Why?
| | Hand Disinfection | 1 | 2004 | 7 | 0.060 |
Why?
| | Detergents | 1 | 2004 | 17 | 0.060 |
Why?
| | Area Under Curve | 1 | 2004 | 178 | 0.060 |
Why?
| | Body Mass Index | 1 | 2007 | 648 | 0.060 |
Why?
| | Cholecalciferol | 1 | 2023 | 22 | 0.060 |
Why?
| | Cross-Over Studies | 1 | 2004 | 223 | 0.060 |
Why?
| | Apoptosis | 1 | 2009 | 1092 | 0.060 |
Why?
| | Vitamins | 1 | 2023 | 64 | 0.060 |
Why?
| | Office Visits | 1 | 2003 | 41 | 0.050 |
Why?
| | Vitamin D | 1 | 2023 | 88 | 0.050 |
Why?
| | Nutritional Status | 1 | 2023 | 136 | 0.050 |
Why?
| | Prognosis | 2 | 2020 | 1957 | 0.050 |
Why?
| | Hospitals | 1 | 2024 | 172 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 458 | 0.050 |
Why?
| | Respiratory Sounds | 1 | 2022 | 48 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2022 | 88 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2020 | 5178 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2004 | 907 | 0.050 |
Why?
| | Risk Management | 1 | 2021 | 32 | 0.050 |
Why?
| | Health Promotion | 1 | 2023 | 264 | 0.050 |
Why?
| | Food | 1 | 2021 | 68 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2019 | 2729 | 0.040 |
Why?
| | Cooking | 1 | 2020 | 18 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2023 | 437 | 0.040 |
Why?
| | Smoking | 1 | 2003 | 506 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 269 | 0.040 |
Why?
| | Tertiary Healthcare | 1 | 2019 | 16 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 225 | 0.040 |
Why?
| | Urban Health | 1 | 2018 | 30 | 0.040 |
Why?
| | Lung | 1 | 2022 | 501 | 0.040 |
Why?
| | Videoconferencing | 1 | 2018 | 37 | 0.040 |
Why?
| | Preventive Health Services | 1 | 2018 | 49 | 0.040 |
Why?
| | Seasons | 1 | 2017 | 81 | 0.040 |
Why?
| | Particulate Matter | 1 | 2017 | 54 | 0.040 |
Why?
| | Rats | 1 | 2003 | 3273 | 0.030 |
Why?
| | Histamine Antagonists | 1 | 2016 | 19 | 0.030 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 85 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 52 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 175 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2017 | 85 | 0.030 |
Why?
| | Egg Proteins | 1 | 2015 | 18 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2018 | 253 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 130 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2016 | 110 | 0.030 |
Why?
| | Middle Aged | 2 | 2015 | 12293 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2015 | 21 | 0.030 |
Why?
| | Milk Proteins | 1 | 2015 | 77 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2016 | 134 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2017 | 693 | 0.030 |
Why?
| | Pregnancy | 1 | 2022 | 2468 | 0.030 |
Why?
| | 2S Albumins, Plant | 1 | 2013 | 7 | 0.030 |
Why?
| | Emergency Treatment | 1 | 2013 | 30 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 61 | 0.030 |
Why?
| | Amikacin | 1 | 2013 | 19 | 0.030 |
Why?
| | Azithromycin | 1 | 2013 | 25 | 0.030 |
Why?
| | Urticaria | 1 | 2013 | 18 | 0.030 |
Why?
| | Equipment Design | 1 | 2013 | 285 | 0.030 |
Why?
| | Poisson Distribution | 1 | 2012 | 34 | 0.030 |
Why?
| | Milk Hypersensitivity | 1 | 2012 | 19 | 0.030 |
Why?
| | Hospitals, University | 1 | 2012 | 77 | 0.020 |
Why?
| | Patient Care Team | 1 | 2013 | 259 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 385 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 1587 | 0.020 |
Why?
| | Health Surveys | 1 | 2012 | 234 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 271 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2012 | 234 | 0.020 |
Why?
| | Clinical Competence | 1 | 2013 | 396 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2009 | 73 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 82 | 0.020 |
Why?
| | Social Class | 1 | 2009 | 95 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 342 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2007 | 83 | 0.020 |
Why?
| | Rural Health Services | 1 | 2009 | 168 | 0.020 |
Why?
| | Cytokines | 1 | 2009 | 607 | 0.020 |
Why?
|
|
Perry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|